BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Feb 19, 2002
 |  BioCentury  |  Emerging Company Profile

Jerini: New look at peptides

Peptides have attracted researchers because they're easy and cheap to manufacture compared to proteins, although they haven't made good drugs because they are poorly absorbed and rapidly degraded and excreted. But they can serve as a starting point for the development of small molecules, and many companies now are trying to systematically transform peptides into peptidomimetics or small molecules that can be administered orally or even nasally.

Peptide and peptidomimetics specialist Jerini AG sees itself well positioned to take advantage of this renewed interest.

"We foresee good opportunities for our business strategy," said CEO Jens Schneider-Mergener, who believes that peptides can be designed to behave just like antibodies without having the disadvantages of antibodies, which can be costly to produce, may show immunogenicity, and usually are not able to enter a cell.

"Most big pharmaceutical companies have abandoned their peptide research units," he said. "But with the renewed interest in these molecules and especially with proteomics, peptides are badly needed. We...

Read the full 798 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >